10-Q: Arrowhead Pharma Soars on FDA Approval, Novartis Deal, and Strong Q1 Earnings

Arrowhead Pharmaceuticals reports a significant financial turnaround in Q1 2026, driven by key regulatory approvals, substantial milestone payments, and a new collaboration with Novartis, alongside a strengthened balance sheet.

Summary

• Arrowhead Pharmaceuticals, Inc. reported a net income attributable to Arrowhead of $30.8 million for the three months ended December 31, 2025, a substantial improvement from a net loss of $173.1 million in the same period of 2024.
• Total revenue for the quarter increased significantly to $264.0 million, up from $2.5 million in the prior year, primarily due to revenue recognition from Sarepta ($229.5 million) and Novartis ($34.2 million) license agreements.
• The company received FDA approval for REDEMPLO (plozasiran) injection for Familial Chylomicronemia Syndrome (FCS) on November 18, 2025, supported by positive Phase 3 PALISADE study data showing an 80% median reduction in triglycerides.
• FDA also granted Breakthrough Therapy designation to plozasiran for severe hypertriglyceridemia (SHTG).
• A $200.0 million milestone payment was earned from Sarepta Therapeutics, Inc. on November 20, 2025, triggered by enrollment targets and dose escalation authorization in a Phase 1/2 clinical study of ARO-DM1, with the payment received in January 2026.
• A global licensing and collaboration agreement with Novartis Pharma AG closed on October 17, 2025, resulting in a $200.0 million upfront payment received on October 23, 2025, with potential for up to $2.0 billion in additional milestones plus royalties.
• The company initiated a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNAi therapeutic for tauopathies including Alzheimer's disease.
• Interim results from Phase 1/2a clinical trials for obesity candidates ARO-INHBE and ARO-ALK7 showed promising data, with ARO-INHBE nearly doubling weight loss with tirzepatide and ARO-ALK7 demonstrating significant adipocyte gene target silencing.
• Subsequent to the quarter, Arrowhead completed upsized offerings of convertible senior notes, common stock, and pre-funded warrants, raising gross proceeds of $930.0 million, further strengthening its balance sheet.
• The China NMPA approved REDEMPLO on January 5, 2026, triggering a $10.0 million regulatory milestone under the Sanofi License Agreement.
• Research and development expenses increased by $40.2 million, or 29%, to $177.2 million, driven by pipeline progression and R&D discovery activities.
• General and administrative expenses increased by $19.1 million, or 71%, to $46.0 million, mainly due to professional services for commercialization and higher headcount.
• The company maintains a senior secured term loan facility of $500.0 million with Sixth Street Lending Partners, with $268.3 million repaid to date and an outstanding balance of $163.1 million net of current portion as of December 31, 2025.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive filing, reflecting a strong financial turnaround, significant regulatory and clinical achievements, and successful strategic partnerships and capital raises that substantially de-risk the company and validate its platform.

Positives

• Shift from a net loss of $173.1 million in Q1 2024 to a net income of $30.8 million in Q1 2025, demonstrating strong financial performance.
• Revenue surged to $264.0 million in Q1 2025 from $2.5 million in Q1 2024, primarily due to significant collaboration agreements.
• FDA approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) on November 18, 2025, marking a significant commercialization milestone.
• Breakthrough Therapy designation granted by the FDA for plozasiran in severe hypertriglyceridemia (SHTG), potentially accelerating its development and review.
• Received a $200.0 million milestone payment from Sarepta Therapeutics for ARO-DM1 program advancement.
• Closed a global licensing and collaboration agreement with Novartis Pharma AG, securing a $200.0 million upfront payment and eligibility for up to $2.0 billion in future milestones plus royalties.
• Positive interim Phase 1/2a clinical trial results for ARO-INHBE and ARO-ALK7, indicating progress in obesity therapeutics and novel RNAi platform capabilities.
• Successful completion of upsized offerings of convertible senior notes, common stock, and pre-funded warrants, raising $930.0 million in gross proceeds and strengthening the balance sheet.
• China NMPA approval of REDEMPLO, triggering an additional $10.0 million regulatory milestone payment.

Negatives

• Increased research and development expenses by 29% to $177.2 million, reflecting higher outsourced clinical trial costs, manufacturing, and toxicity studies.
• General and administrative expenses rose by 71% to $46.0 million, mainly due to professional services for commercialization and increased headcount.
• Cash, cash equivalents, and restricted cash decreased by $25.0 million during the quarter, partially due to credit facility repayments and investment purchases.
• The company is involved in a patent infringement lawsuit with Ionis Pharmaceuticals, Inc. regarding plozasiran, although Ionis' motion to dismiss was granted, the company intends to vigorously defend itself.

Risks

• Failure to make timely payments of principal, interest, or fees on the Credit Facility could trigger an Event of Default.
• Breach or default under other material indebtedness agreements (exceeding $1.5 million) could lead to acceleration of the Credit Facility.
• Any false or materially misleading representations or warranties made in Loan Documents could constitute an Event of Default.
• Failure to comply with covenants, including maintaining minimum Qualified Cash, restrictions on asset sales, or restricted junior payments, could result in an Event of Default.
• Involuntary or voluntary bankruptcy, insolvency, or similar proceedings against the company or its subsidiaries would trigger an Event of Default.
• Unsatisfied money judgments, writs, or warrants of attachment exceeding $1.5 million could lead to an Event of Default.
• Dissolution or split-up of any Loan Party or material subsidiary could constitute an Event of Default.
• A Change of Control event, as defined in the Financing Agreement, would trigger an Event of Default.
• Invalidation or unenforceability of the Guaranty or Collateral Documents, or failure to maintain perfected Liens on Collateral, could lead to an Event of Default.
• Indictment or criminal proceedings against the company or its subsidiaries leading to forfeiture of material property could have a Material Adverse Effect.
• Occurrence of an ERISA Event that results in a Material Adverse Effect.
• A Regulatory Action or Material Regulatory Liability with respect to any Product that results in a Material Adverse Effect.
• Cessation of a substantial part of the company's business for more than 30 days, or material damage/loss of Collateral causing cessation of revenue-producing activities for more than 30 days, could trigger an Event of Default.

Future Outlook

The company expects to have sufficient liquidity to fund its operations through at least the next twelve months from the date of the issuance of these unaudited consolidated financial statements, based on current cash and investment resources and its operating plan. The company is eligible to receive up to $15.3 billion in additional developmental, regulatory, and sales milestones from partnered programs and various royalties on net sales.

Management Comments

• "Based upon the Company's current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund its operations through at least the next twelve months from the date of the issuance of these unaudited consolidated financial statements."
• "The increase in net income attributable to Arrowhead Pharmaceuticals, Inc. for the three months ended December 31, 2025 compared to the same period of 2024 was primarily due to an increase in revenue from the Sarepta Collaboration Agreement, partially offset by higher research and development expenses, associated with the expansion of the Company's pipeline and progression through clinical trial phases."

Industry Context

StockSavvy.ai notes that Arrowhead Pharmaceuticals' recent FDA approval for REDEMPLO and the Breakthrough Therapy designation for plozasiran position it favorably in the cardiometabolic disease market, particularly for rare lipid disorders. The new collaboration with Novartis for CNS programs and the expansion into obesity therapeutics with ARO-INHBE and ARO-ALK7 demonstrate a diversified pipeline strategy, leveraging its proprietary TRiM platform to target multiple genes simultaneously. This multi-pronged approach is critical in the competitive RNAi therapeutic space, where companies like Alnylam and Ionis are also active, and could provide multiple shots on goal for future commercial success.

Comparison to Industry Standards

• The FDA approval of REDEMPLO for FCS places Arrowhead in a select group of companies with approved RNAi therapeutics, comparable to Alnylam's ONPATTRO or Amgen's Repatha (though Repatha is not an RNAi therapeutic, it targets PCSK9 for lipid management). The median triglyceride reduction of -80% in the PALISADE study is a strong clinical outcome for FCS patients, a rare disease with high unmet need.
• The Breakthrough Therapy designation for plozasiran in SHTG is a significant regulatory achievement, similar to designations received by other innovative therapies, which can expedite development and review timelines, potentially bringing the drug to market faster than standard pathways.
• The $200.0 million milestone payment from Sarepta for ARO-DM1 advancement reflects successful progression in a rare genetic muscle disease program, aligning with industry trends of significant upfront and milestone payments for promising assets in specialized therapeutic areas.
• The Novartis collaboration, with a $200.0 million upfront payment and potential for up to $2.0 billion in milestones, is a substantial deal, comparable to other large pharma-biotech partnerships for early-stage assets, indicating strong validation of Arrowhead's TRiM platform and CNS pipeline.
• The positive interim Phase 1/2a data for ARO-INHBE and ARO-ALK7 in obesity, particularly the dual-gene targeting approach, represents a novel strategy in a highly competitive and large market, potentially differentiating Arrowhead from traditional obesity drug developers like Eli Lilly (tirzepatide) and Novo Nordisk (semaglutide) by offering enhanced efficacy or a unique mechanism of action.

Management Changes

Corporate Governance

Legal Proceedings

• On September 10, 2025, the company filed a Complaint for Declaratory Judgment against Ionis Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware, seeking to declare U.S. Patent No. 9,593,333 invalid and not infringed by plozasiran.
• On September 11, 2025, Ionis Pharmaceuticals, Inc. filed a Complaint for Patent Infringement against the company in the U.S. District Court for the Central District of California, alleging infringement of the '333 patent by plozasiran and seeking damages.
• On December 23, 2025, the court granted Ionis' motion to dismiss in the patent dispute.
• The company disputes the allegations of wrongdoing and intends to vigorously defend itself.

Related Party Transactions

• Visirna Therapeutics, Inc. (a majority-owned subsidiary) entered into an Asset Transfer Agreement with Bisirna Therapeutics, Inc. on January 15, 2026. Bisirna is considered a related party because the CEO of Visirna is also the owner of Bisirna.
• The transaction involved Visirna selling and transferring certain R&D technology assets and rights to Bisirna for a purchase price of $19.0 million, payable as $9.0 million in paid-in-full warrants and $10.0 million of Bisirna Series A preferred shares.

Stakeholder Impact

• **Shareholders:** Positive impact due to strong financial performance, significant revenue growth, major regulatory approvals (FDA, NMPA), new collaboration agreements, and successful capital raises, which collectively enhance shareholder value and reduce financial risk. The stock repurchase from Sarepta also indicates active capital management.
• **Employees:** Increased headcount and expansion of R&D activities suggest growth opportunities and stability. Stock-based compensation remains a significant component of overall compensation.
• **Customers/Patients:** FDA approval of REDEMPLO provides a new treatment option for Familial Chylomicronemia Syndrome (FCS) patients. Breakthrough Therapy designation for plozasiran in SHTG indicates potential for another important therapeutic.
• **Lenders (Sixth Street Lending Partners):** The company has made significant repayments on its credit facility and successfully raised additional capital, improving its ability to meet debt obligations. The MOIC payment structure provides clear returns for lenders.
• **Collaboration Partners (Sarepta, Novartis, GSK, Takeda, Sanofi):** Continued progress in partnered programs and achievement of milestones strengthen these relationships and validate the company's platform and development capabilities.

Next Steps

• Continue clinical development of ARO-DIMER-PA (Phase 1/2a clinical trial).
• Continue clinical development of ARO-MAPT (Phase 1/2a clinical trial).
• Further development and commercialization of plozasiran for SHTG following Breakthrough Therapy designation.
• Ongoing research and development activities for partnered candidates with Sarepta, Novartis, GSK, and Takeda.
• Integration of new accounting standards (ASU 2024-03 and ASU 2023-09) in future financial reporting.
• Vigorously defend against the patent infringement lawsuit filed by Ionis Pharmaceuticals, Inc.

Key Dates

Recommendation

The filing presents a compelling case for a strong buy. The company has achieved a significant financial turnaround, moving from a substantial net loss to a net income, driven by robust revenue growth from strategic collaborations. Key regulatory milestones, including FDA approval for REDEMPLO and Breakthrough Therapy designation for plozasiran, validate its pipeline and open new commercial avenues. The new collaboration with Novartis and the substantial milestone payments from Sarepta further de-risk the company's development programs and provide significant non-dilutive funding. The recent upsized capital raise has also substantially strengthened the balance sheet, providing ample liquidity for future operations and R&D expansion. While R&D and G&A expenses have increased, this is a natural consequence of pipeline progression and commercialization efforts, which are yielding positive results. The overall trajectory and recent achievements indicate strong momentum and future growth potential.

Keywords

RNAi therapeutics, biotechnology, drug development, clinical trials, FDA approval, Breakthrough Therapy, FCS, SHTG, plozasiran, REDEMPLO, Sarepta, Novartis, milestone payments, licensing agreement, capital raise, convertible notes, stock offering, ARO-DM1, ARO-MAPT, ARO-INHBE, ARO-ALK7, obesity, Alzheimer's disease, myotonic dystrophy, hepatitis B, alpha-1 antitrypsin deficiency, atherosclerotic cardiovascular disease, gene silencing, TRiM platform, financial results, SEC filing